Lilly vs Novo Nordisk. Why 2026 Could Redefine the Obesity Drug Market [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Novo Nordisk and Eli Lilly lead the wave. Novo's oral semaglutide may win approval this year and reach patients early next year. Lilly's orforglipron aims for approval by the end of the first quarter of 2026 and a second-quarter launch. Warning! GuruFocus has detected 4 Warning Signs with NVDA. Is LLY fairly valued? Test your thesis with our free DCF calculator. Pills offer convenience and lower manufacturing costs than injectables. Trials show orforglipron trimmed body weight about 12.4% after 72 weeks while oral semaglutide showed roughly 16.6% after 64 weeks; injectables such as Zepbound often deliver larger losses. A November deal to expand Medicare and Medicaid coverage, with copays capped near $50 a month starting in April, could widen use among older and lower-income patients. That would materially increase the addressable market. Altogether, 2026 has a real potential to turn the tables on obesity, haddies, pills, and wider coverage: the obstructed gate can be opened
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- American Heart Association (AHA) Scientific Sessions Highlights Report 2025: Market Opportunities Lie in Novel Therapeutics Like Semaglutide, VK2735, SHR-1918, BacNav, and Satralizumab [Yahoo! Finance]Yahoo! Finance
- Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead? [Yahoo! Finance]Yahoo! Finance
- Is Novo Nordisk Now Attractive After a 48.8% Slide and DCF Reassessment? [Yahoo! Finance]Yahoo! Finance
- While the price of 15 prescription drugs is set to drop, only 5.3M Americans will benefit. Here's what you need to know [Yahoo! Finance]Yahoo! Finance
- ?Novo Nordisk (NVO) Receives Positive Opinion For Wegovy By European Medicines Agency [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website